clearance, progression (to CIN2+), and persistence
Fig. 2 · Panel Cumulative_Incidence_of_Clearance_and_Progression
Panel Cumulative_Incidence_of_Clearance_and_Progression 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Qi Chen, Jiali Quan, Kongxin Zhu, Linchen Lan, Jiaoxi Lu, Linfeng Zhu, Bin Zhang, Guohua Zhong, Zhaofeng Bi, Shoujie Huang, Yingying Su, Lihui Wei, Youlin Qiao, Jun Zhang, Ting Wu, Ningshao Xia
Nat Commun 17(1) 1677
Existing evidence regarding the impact of vaccination on the natural history of high-risk human papillomavirus (HPV) infections remains limited, understanding such effects is essential for optimizing cervical cancer screening in post-vaccination era. Using 10-year follow-up data from a phase 3 randomized trial of the Escherichia coli-produced HPV-16/18 bivalent vaccine (NCT01735006) and its extension study (NCT05045755, NCT04969445), we compared the spectra and natural history (persistence, clearance, and progression) of high-risk HPV infections between vaccinated and unvaccinated females aged 18-45 years. Data was analyzed using the Cox regression and the competing risk model. Our findings indicate that vaccination reduces the burden of HPV-16/18-associated lesions (HR = 0.12, p = 0.0041) primarily by preventing incident infections (HR = 0.45, p < 0.0001) and modifying the natural history of breakthrough infections (enhancing clearance: 98.5% vs. 93.8%, p < 0.0001; and attenuating progression: 1.5% vs. 6.2%, p = 0.0420). Conversely, the elevated burden of HPV-52-associated lesions (HR = 3.06, p = 0.0303) observed in the vaccine group stems mainly from altered natural history (reduced clearance: 90.3% vs. 97.9%, p = 0.0144; and increased progression: 9.7% vs. 2.1%, p = 0.0421), rather than an increase in incidence (HR = 1.09, p = 0.2669). In this work, the observed shifts in HPV infection profiles and natural history between vaccinated and unvaccinated populations suggest that cervical cancer screening recommendations may warrant adjustment for vaccinated individuals.
1 个 Figure · 1 个 KM 面板
Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-16/18 infections in the vaccine and control group. CIN2 + , cervical intraepithelial neoplasia grade 2 or greater; HR-HPV, high-risk human papillomavirus; FDR, false discovery rate. In competing risk analyses, the estimates for progression (to CIN2 + ), clearance, and persistence add up to 100% at each time point. A stratified Benjamini-Hochberg FDR procedure was used to adjust for multiple comparisons. All statistical tests were two-sided, with a significance level of α = 0.05.
Fig. 2 · Panel Cumulative_Incidence_of_Clearance_and_Progression
Panel Cumulative_Incidence_of_Clearance_and_Progression 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。